With sales of many blockbuster drugs being cannibalised by generic competitors, pharmaceutical companies are populating their pipelines with candidates directed at novel targets, enhancing development and commercialisation opportunities. The opportunities for medium-sized discovery and development companies is increasing as the dynamic of the market changes.
Chichester, West Sussex. EGFr, such as Roche’s Avastin and Herceptin, it is the development of novel biological approaches that will bring a sea change to the way cancer is treated. Current clinical trial data are showing impressive improvements in controlling solid tumours in leading sectors such as lung, breast and prostate cancers and a number of these drugs could be on the market in 5 years time.
Sue Viney, senior oncology analyst at Espicom and the report’s author comments "Novel approaches in the development of new drugs along with broader mechanisms of action for existing therapeutic approaches will bring real clinical benefits to patients and will have fewer side effects. The challenge for industry and society alike will be the affordability of these products in times of economic restraint".
For further information on the report please visit Targeted Cancer Drugs.
Espicom Business Intelligence is a leading publisher of medical and pharmaceutical market analysis. With over 50,000 users worldwide its reports, news services and analysis products are used regularly by key decision makers in industry, government and commerce. A full catalogue can be found on the web at http://www.espicom.com.
For further information and review copies contact
Ian Taylor, Research Director
Tel:+44 (0) 1243 756019
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/2/prweb9202950.htm